Search results for " PD"

Infinitely many solutions for a perturbed nonlinear Navier boundary value problem involving the -biharmonic

2012

By using critical point theory, we establish the existence of infinitely many weak solutions for a class of elliptic Navier boundary value problems depending on two parameters and involving the p-biharmonic operator. © 2012 Elsevier Ltd. All rights reserved.

Two Nontrivial Solutions for Robin Problems Driven by a p–Laplacian Operator

2020

By variational methods and critical point theorems, we show the existence of two nontrivial solutions for a nonlinear elliptic problem under Robin condition and when the nonlinearty satisfies the usual Ambrosetti-Rabinowitz condition.

Fractional differential equations solved by using Mellin transform

2014

In this paper, the solution of the multi-order differential equations, by using Mellin Transform, is proposed. It is shown that the problem related to the shift of the real part of the argument of the transformed function, arising when the Mellin integral operates on the fractional derivatives, may be overcame. Then, the solution may be found for any fractional differential equation involving multi-order fractional derivatives (or integrals). The solution is found in the Mellin domain, by solving a linear set of algebraic equations, whose inverse transform gives the solution of the fractional differential equation at hands.

Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER…

2020

TPS468 Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care palliative 1st-line therapy for advanced HER2+ GEJ/GC patients (pts). M, an Fc-engineered anti-HER2 mAb, targets the same HER2 epitope but with higher affinity for both 158V (high binding) and 158F (low binding) alleles of activating Fc receptor CD16A. M coordinately enhanced both innate and adaptive immunity, including antigen-specific T-cell responses to HER2. PD-1 and LAG-3 are T-cell checkpoint molecules that suppress T-cell function. MGA012 (INCMGA00012) is a humanized, hinge-stabilized, IgG4 κ anti-PD-1 mAb blocking binding of PD-L1 or PD-L2 to PD-1. MGD013 is a humanized Fc-bearing bi…

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metasta…

2021

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC…

2020

Introduction: Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab. Methods: This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treat…

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

2014

Abstract: Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent cancer immunoediting has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy …

1063P Profiling of peripheral T cell receptor beta chain repertoire in non-small cell lung cancer (NSCLC) patients treated with anti-PD1

2020

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ g…

2020

Existence and stability of periodic solutions in a neural field equation

2017

We study the existence and linear stability of stationary periodic solutions to a neural field model, an intergo-differential equation of the Hammerstein type. Under the assumption that the activation function is a discontinuous step function and the kernel is decaying sufficiently fast, we formulate necessary and sufficient conditions for the existence of a special class of solutions that we call 1-bump periodic solutions. We then analyze the stability of these solutions by studying the spectrum of the Frechet derivative of the corresponding Hammerstein operator. We prove that the spectrum of this operator agrees up to zero with the spectrum of a block Laurent operator. We show that the no…